Financials Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 18:13:45 12/07/2024 BST 5-day change 1st Jan Change
224.2 USD +2.19% Intraday chart for Iqvia Holdings Inc. +7.73% -3.11%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,981 34,352 53,900 38,056 42,227 39,982 - -
Enterprise Value (EV) 1 40,789 44,983 64,659 49,587 54,524 51,744 51,207 49,982
P/E ratio 161 x 125 x 57 x 35.8 x 31.7 x 30 x 25.2 x 21.5 x
Yield - - - - - - - -
Capitalization / Revenue 2.7 x 3.02 x 3.88 x 2.64 x 2.82 x 2.59 x 2.42 x 2.27 x
EV / Revenue 3.68 x 3.96 x 4.66 x 3.44 x 3.64 x 3.35 x 3.1 x 2.83 x
EV / EBITDA 17 x 18.9 x 21.4 x 14.8 x 15.3 x 13.9 x 12.7 x 11.5 x
EV / FCF 48.8 x 33.5 x 28.1 x 31.3 x 36.3 x 29.1 x 23.7 x 20.1 x
FCF Yield 2.05% 2.99% 3.56% 3.2% 2.75% 3.44% 4.22% 4.99%
Price to Book 4.95 x 5.71 x 9.11 x 6.6 x 7.05 x 5.86 x 5.24 x 4.49 x
Nbr of stocks (in thousands) 194,038 191,726 191,040 185,740 182,500 182,200 - -
Reference price 2 154.5 179.2 282.1 204.9 231.4 219.4 219.4 219.4
Announcement Date 12/02/20 10/02/21 15/02/22 10/02/23 14/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,088 11,359 13,874 14,410 14,984 15,466 16,540 17,644
EBITDA 1 2,400 2,384 3,022 3,346 3,569 3,733 4,048 4,350
EBIT 1 2,112 2,030 2,591 2,779 3,050 3,142 3,424 3,714
Operating Margin 19.05% 17.87% 18.68% 19.29% 20.36% 20.31% 20.7% 21.05%
Earnings before Tax (EBT) 1 352 373 1,128 1,363 1,459 1,638 1,969 2,305
Net income 1 191 279 966 1,091 1,358 1,335 1,572 1,814
Net margin 1.72% 2.46% 6.96% 7.57% 9.06% 8.63% 9.5% 10.28%
EPS 2 0.9600 1.430 4.950 5.720 7.290 7.323 8.712 10.20
Free Cash Flow 1 835 1,343 2,302 1,586 1,500 1,778 2,162 2,492
FCF margin 7.53% 11.82% 16.59% 11.01% 10.01% 11.5% 13.07% 14.13%
FCF Conversion (EBITDA) 34.79% 56.33% 76.17% 47.4% 42.03% 47.63% 53.4% 57.29%
FCF Conversion (Net income) 437.17% 481.36% 238.3% 145.37% 110.46% 133.19% 137.5% 137.39%
Dividend per Share 2 - - - - - - - -
Announcement Date 12/02/20 10/02/21 15/02/22 10/02/23 14/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3,636 3,568 3,541 3,562 3,739 3,652 3,728 3,736 3,868 3,737 3,790 3,867 4,060 3,995 4,094
EBITDA 1 828 812 800 814 920 851 864 888 966 862 883.8 954 1,039 926.9 973.7
EBIT 1 704 691 682 694 712 721 737 747 821 738 746.3 798.6 870.6 789.6 822
Operating Margin 19.36% 19.37% 19.26% 19.48% 19.04% 19.74% 19.77% 19.99% 21.23% 19.75% 19.69% 20.65% 21.44% 19.76% 20.08%
Earnings before Tax (EBT) 1 376 400 328 360 275 362 375 349 373 340 371.8 426 504.2 414.3 452.7
Net income 1 318 325 256 283 227 289 297 303 469 288 304.3 346 407.3 328 361
Net margin 8.75% 9.11% 7.23% 7.94% 6.07% 7.91% 7.97% 8.11% 12.13% 7.71% 8.03% 8.95% 10.03% 8.21% 8.82%
EPS 2 1.630 1.680 1.340 1.490 1.200 1.530 1.590 1.630 2.540 1.560 1.621 1.847 2.176 1.820 1.998
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 15/02/22 27/04/22 21/07/22 26/10/22 10/02/23 27/04/23 01/08/23 01/11/23 14/02/24 02/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 10,808 10,631 10,759 11,531 12,297 11,762 11,225 10,000
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.503 x 4.459 x 3.56 x 3.446 x 3.446 x 3.151 x 2.773 x 2.299 x
Free Cash Flow 1 835 1,343 2,302 1,586 1,500 1,778 2,162 2,492
ROE (net income / shareholders' equity) 20.1% 20.9% 29.2% 32.8% 32% 31.3% 31.8% 31.9%
ROA (Net income/ Total Assets) 5.57% 1.17% 7.15% 7.74% 5.22% 6.07% 6.69% 7.56%
Assets 1 3,428 23,907 13,517 14,088 26,009 22,003 23,495 24,009
Book Value Per Share 2 31.20 31.40 31.00 31.00 32.80 37.50 41.80 48.90
Cash Flow per Share 2 7.100 10.00 15.10 11.90 11.50 14.90 17.20 19.40
Capex 1 582 616 640 674 649 634 661 718
Capex / Sales 5.25% 5.42% 4.61% 4.68% 4.33% 4.1% 3.99% 4.07%
Announcement Date 12/02/20 10/02/21 15/02/22 10/02/23 14/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
219.4 USD
Average target price
269.2 USD
Spread / Average Target
+22.70%
Consensus
  1. Stock Market
  2. Equities
  3. IQV Stock
  4. Financials Iqvia Holdings Inc.